Eppendorf Announces Best New General Lab Product Win
Eppendorf announces that it won the Best New General Lab Product at the Scientists’ Choice Awards.
Eppendorf announced that SelectScience named it the Best New General Lab Product winner at the Scientists’ Choice Awards. The awards, which were announced at Pittcon 2015 in New Orleans, LA, are nominated and voted on by SelectScience’s audience of purchasing scientists, according to the website. Eppendorf’s Multipette M4/Repeater M4, a hand-held serial pipetting instrument, was given the award in recognition of a product that has “significantly contributed towards laboratory efforts in 2014,” according to the press release.
“This year, more than 7400 scientists worldwide participated in the Scientists' Choice Awards, celebrating the most innovative technologies of 2014 from the most successful manufacturers. The Reviewers' Choice Awards showcase the power of impartial reviews and enable scientists to make informed purchasing decisions,” said Kerry Parker, editor-in-chief of SelectScience, in a press release.
Source: Eppendorf
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
